New drug combo shows promise for Tough-to-Treat stomach cancer

NCT ID NCT03686488

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 study tested a combination of two drugs, TAS 102 (Lonsurf) and ramucirumab (Cyramza), in 23 patients with advanced stomach or gastroesophageal junction cancer that had stopped responding to other treatments. The goal was to see if the combo was safe and could help patients live longer. The study is complete, and results suggest this approach may offer a new option for patients with few alternatives.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TAS 102 (Lonsurf) and ramucirumab (Cyramza)
What this could lead to
If successful, this combination could offer a new treatment option for patients with advanced stomach cancer who have run out of standard therapies, potentially extending survival.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to all patients. The combination may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.